Pharmacoeconomic
Mostrando 1-12 de 14 artigos, teses e dissertações.
-
1. Perception of castration value over cost in the metastatic prostate cancer scenario: a contemporary pharmacoeconomic perspective
International braz j urol. Publicado em: 2022
-
2. Cost-consequence analysis of Pharmaceutical Care program for systemic arterial hypertension in the public health system in Brazil
ABSTRACT In Brazil, 80% of hypertensive patients have no blood pressure controlled, this fact has caused severe financial consequences for the public health system (PHS) and the Pharmaceutical Care (PC) has emerged as an effective alternative. The aim of this study was to analyze the costs and outcomes of systemic arterial hypertension (SAH) for conventional
Braz. J. Pharm. Sci.. Publicado em: 01/02/2018
-
3. Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system
ABSTRACT Human insulin is provided by the Brazilian Public Health System (BPHS) for the treatment of diabetes, however, legal proceedings to acquire insulin analogs have burdened the BPHS health system. The aim of this study was to perform a cost-effectiveness analysis to compare insulin analogs and human insulins. This is a pharmacoeconomic study of cost-ef
Braz. J. Pharm. Sci.. Publicado em: 13/11/2017
-
4. Pharmacoeconomic analysis of clinical pharmacy in HIV-positive patients / Análise farmacoeconômica da farmácia clínica em pacientes HIV positivo = : Pharmacoeconomic analysis of clinical pharmacy in HIV-positive patients
Studies demonstrate that clinical pharmacy with HIV-positive patients can lead to positive clinical results. However, few studies evaluate its economic impact. The objective of this study is to verify the economic impact of pharmaceutical care with HIV-positive patients. A prospective controlled study with systematic sampling by quota with controls paired by
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 14/09/2012
-
5. Oxybutynin and tolterodine for treatment of neurogenic detrusor overactivity: a pharmacoeconomic evaluation in the Brazilian context
A terapia antimuscarínica é vista como primeira escolha para o tratamento da hiperatividade detrusora de origem neurológica (HDON). No entanto, a maioria dos antimuscarínicos existentes é amplamente estudada em pacientes portadores de hiperatividade detrusora idiopática. Assim, existe escassez de pesquisas que avaliam esses fármacos na problemática d
Brazilian Journal of Pharmaceutical Sciences. Publicado em: 2012-06
-
6. Alternativas de tratamento para hepatite viral crônica B: análise de custo-efetividade
Introduction: Hepatitis B is one of the most common infectious diseases worldwide and has been showing increasing expenditures in the Brazilian Unified Healh System (SUS). Objectives: To perform a pharmacoeconomic and epidemiological evaluation of interferon and lamivudine classified as high costs in SUS and utilized for the treatment of adults with chronic
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 17/02/2011
-
7. To circ or not to circ: clinical and pharmacoeconomic outcomes of a prospective trial of topical steroid versus primary circumcision
PURPOSE: To compare the efficacy and costs of circumcision versus topical treatment using a prospective pharmacoeconomic protocol. MATERIALS AND METHODS: We treated 59 patients (3-10 years of age) randomized into two groups: 29 underwent an 8-week course of topical treatment with 0.2% betamethasone-hyaluronidase cream twice a day; and 30 underwent circumcisi
International braz j urol. Publicado em: 2010-02
-
8. Análise farmacoeconômica do tratamento do câncer colorretal metastático com bevacizumabe no Brasil / Pharmacoeconomic analysis of metastatic colorectal cancer with bevacizumab in Brazil
No presente estudo realizou-se a análise custo-efetividade das terapias antineoplásicas IFL (irinotecano, 5-fluorouracil e leucovorin) e IFL+BV (IFL associado ao bevacizumabe) empregado no tratamento do câncer colorretal metastático em primeira linha. Estimou o custo direto de medicamentos, materiais e recursos humanos. A efetividade dos protocolos foi m
Publicado em: 2007
-
9. Pharmacoeconomics applied to chronic hepatitis C
Life expectancy has increased over the last century as it had never been before. This is the result of a combination of many favorable variables such as level of education, improved socio-economic environment and development of medicine. However, new improvements demand heavy investment. Thus, the incorporation of medical technology became a health and econo
Brazilian Journal of Infectious Diseases. Publicado em: 2006-02
-
10. La aplicación práctica de la farmacoeconomía en la utilización de los medicamentos en Cuba
The purpose of this work is to expose how pharmacoeconomic studies contribute to render a rational and efficient use to drugs. As a consequence of the present study focusing on pharmacoeconomics by the Cuban-Republic sanitary authorities, the pharmaceutical industry is becoming interested in such analytical techniques and has started to use them for developi
Revista Brasileira de Ciências Farmacêuticas. Publicado em: 2004-12
-
11. Farmacoeconomía: eficiencia y uso racional de los medicamentos
This paper is a discussion about pharmacoeconomics contributes to increase the efficiency levels in the field of drug use. By this discipline's work guidelines, different pharmacoeconomic applications will be able to be performed, both in the field of sanitary-services offering and in the process of obtaining new drugs by the pharmaceutical industry. As a re
Revista Brasileira de Ciências Farmacêuticas. Publicado em: 2004-12
-
12. Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil
Hepatitis C virus (HCV) infection is a serious public health problem, since 80% to 85% of HCV carriers develop a persistent infection that can progress into liver cirrhosis and hepatocarcinoma. Considering that the response of hepatitis C patients to combination therapy with interferon and ribavirin depends on HCV characteristics as well as on host features,
Brazilian Journal of Infectious Diseases. Publicado em: 2004-10